Follow us on:

Arix Bioscience a diversified portfolio and an IRR of 20% since inception (Analyst Interview)

Arix Bioscience plc (LON:ARIX) is the topic of conversation when Dr Martin Hall, Analyst at Hardman & Co joins DirectorsTalk. Martin explains how Arix differs from other investment vehicles, how it has performed well since it released its interim results, trading relative to the NAV, narrowing the discount, the risks involved and what to expect from the company looking forward.

Questions we ask Dr Martin Hall:

Q1: Can you tell us what Arix does and how it differs from other investment vehicles?
Q2: The shares of Arix Bioscience have performed well since it released its interim results for 2020. Can you say what has been behind this movement?
Q3: So, how are the shares trading relative to the NAV?
Q4: What do you think will make this discount narrow?
Q5: What are the risks?
Q6: What is coming up in the near future?

Arix Bioscience is a United Kingdom-based healthcare and life science company. The Company is a holding company that is focused on generating value from the development and commercialization of technologies and discoveries.

You might also enjoy reading ICG Enterprise Trust Operating companies’ widening margins and strong EBITDA growth (VIDEO)

Find more news, interviews, share price & company profile here for:

Hardman & Co

Share this interview

Other Interviews

ANALYST INTERVIEW: PHOENIX COPPER LTD First stage in potential world-class copper mine September 10, 2019
INTERVIEW: Hardman & Co Renewable Energy Infrastructure Funds August 15, 2019
INTERVIEW: ARBUTHNOT BANKING GROUP – 1H’19 results: diversified, low-risk growth continues August 9, 2019
INTERVIEW: Volta Finance – Questions from the Hardman Investor Forum July 12, 2019
INTERVIEW: The International Property Securities Exchange July 3, 2019
INTERVIEW: Non Standard Finance fundamental outlook remains unchanged July 2, 2019
INTERVIEW: RM Secured Direct lending ‘Predictable revenue streams generating high yield’ June 24, 2019
INTERVIEW: Morses Club ‘reliable, steady state with modest organic volume growth’ June 21, 2019
INTERVIEW: Hardman & Co – The value in Urban Logistics June 6, 2019
INTERVIEW: Mark Thomas – Understanding the deepest discounts on investment companies May 31, 2019

More News

Search

Useful links

Disclaimer

You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular stock, share, security, portfolio of securities, transaction, investment strategy, or other matter. We openly disclose that we and our contributors may have interests in investments and/or providers of services referred to within the website and that we receive remuneration from certain of the companies referred to on this website.

© 2024 – DirectorsTalk Interviews. All rights reserved. Reproduction in whole or in part, in any form or medium without express written permission is prohibited.